Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ADRX Catalyst Timeline
Dated clinical, regulatory and corporate events for ADARx Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ADARx Pharmaceuticals, Inc.
Upcoming catalysts 2
Event history 12
Past FDA Catalysts and PDUFA Decisions
How ADRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADX-324 Small MoleculesNCT05691361 | Hereditary Angioedema | Phase 3 | ACTIVE NOT_RECRUITING | 233 | Dec 31, 2027 | ||||||
| ADX-038 Small MoleculesNCT06989359 | IgAN | Phase 2 | RECRUITING | 45 | Jun 1, 2029 | ||||||
| ADX-038 Small MoleculesNCT06990269 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | RECRUITING | 240 | Aug 30, 2030 | ||||||
| ADX-038 Small MoleculesNCT07522099 | Immunoglobulin A Nephropathy (IgAN) | Phase 2 | RECRUITING | 30 | Jan 21, 2029 | ||||||
| ADX-038 Small MoleculesNCT05876312 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1/2 | RECRUITING | 50 | Jul 31, 2028 | ||||||
| ADX-626 RNA-Based TherapiesNCT07081503 | Undisclosed | Phase 1 | RECRUITING | 44 | Jun 30, 2027 | ||||||
| ADX-850 Small MoleculesNCT06205628 | Hypertension | Phase 1 | ACTIVE NOT_RECRUITING | 28 | Mar 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ADRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| George SimeonDirector, 10% Owner | BuyOffering | 592,593 592,593 held | $17.00 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ADRX for Q2 2026. | ||||
Ownership Trends
ADRX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How ADRX ranks across every disease it competes in
ADRX News
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
ADARx Pharmaceuticals reported strong financial results for Q3 2026, highlighted by a successful IPO that raised approximately $602.5 million. The company is advancing three Phase 2 clinical trials for agazisiran and received Fast Track designation for onvuzosiran. With a cash position expected to last into 2030, ADARx is well-positioned for continued growth.
Read more →ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
ADARx Pharmaceuticals will have CEO Zhen Li participate in a fireside chat at the UBS Global Biopharma Conference on November 16, 2026. The event will be held in London and will include a live webcast. ADARx focuses on developing siRNA therapeutics for various diseases, with several programs in clinical stages.
Read more →ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals announced the full exercise of underwriters' option to purchase an additional 3,937,500 shares in its IPO, raising total gross proceeds to approximately $513.2 million. The offering closed on October 1, 2026, with a total of 30,187,500 shares sold. Additionally, AbbVie purchased 5,255,542 shares in a concurrent private placement, bringing total proceeds to about $602.5 million.
Read more →ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
ADARx Pharmaceuticals has announced the pricing of its upsized initial public offering, raising approximately $446.3 million by offering 26,250,000 shares at $17.00 each. The shares are expected to begin trading on Nasdaq on September 25, 2026, with a concurrent private placement involving AbbVie. The total gross proceeds from both offerings could reach around $535.2 million.
Read more →ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE
ADARx Pharmaceuticals has received FDA Fast Track designation for onvuzosiran, a siRNA therapeutic aimed at preventing hereditary angioedema (HAE) attacks. This designation is a significant milestone as it facilitates the drug's development and review process. Onvuzosiran is currently in Phase 3 trials and aims to offer improved control over HAE compared to existing treatments.
Read more →ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
ADARx Pharmaceuticals has expanded its leadership team by appointing Ying Huang, Ph.D., to its Board of Directors and Robert Ackles as Chief People Officer. Dr. Huang's extensive experience in biotech and capital markets will support ADARx's growth strategy. Ackles brings nearly three decades of experience in building effective people strategies to enhance the company's culture and execution.
Read more →ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress
ADARx Pharmaceuticals will present Phase 1/2 data for onvuzosiran at the 2026 EAACI Congress. This investigational siRNA therapy targets hereditary angioedema (HAE) and aims to reduce plasma kallikrein levels. The ongoing Phase 3 STOP-HAE trial is designed to evaluate its efficacy in preventing HAE attacks.
Read more →ADARx Pharmaceuticals Expands Leadership Team with Appointment of Healthcare Investment Banking Veteran Ryan Fisk as Chief Financial Officer and Chief Business Officer
ADARx Pharmaceuticals appointed Ryan Fisk as Chief Financial Officer and Chief Business Officer. Fisk, with over 20 years of investment banking experience, will lead finance and corporate development. His background includes advising biotech companies on strategic transactions worth over $135 billion. ADARx focuses on RNA therapeutics across multiple therapeutic areas.
Read more →ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE
ADARx Pharmaceuticals announced positive Phase 1/2 data for onvuzosiran, an investigational siRNA therapy for hereditary angioedema (HAE). The treatment demonstrated significant reductions in plasma kallikrein levels, with 80% reductions maintaining through Day 169. The ongoing Phase 3 STOP-HAE trial aims to further evaluate its efficacy and safety.
Read more →ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
ADARx Pharmaceuticals announced it will present Phase 1/2 data and Phase 3 design for onvuzosiran (ADX-324) at the 2026 AAAAI Annual Meeting. This investigational siRNA therapy targets hereditary angioedema (HAE) by inhibiting prekallikrein. The presentation is scheduled for February 27, 2026, in Philadelphia, PA.
Read more →ADARx Pharmaceuticals Appoints Donald Fong, M.D., as Chief Medical Officer
ADARx Pharmaceuticals appointed Dr. Donald Fong as Chief Medical Officer to lead its clinical development strategy. Dr. Fong has over 25 years of experience in clinical development across various therapeutic areas. His role will focus on advancing ADARx's ongoing Phase 2 and Phase 3 clinical trials and other programs.
Read more →ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
ADARx Pharmaceuticals appointed Dr. Mary Tagliaferri to its Board of Directors. With over three decades of experience in clinical development and regulatory strategy, she will enhance the company's leadership. Dr. Tagliaferri currently serves as Chief Medical Officer at Nektar Therapeutics and has a strong background in oncology and immunology.
Read more →